A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 115 participants.

Also called NCT06973031

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 115 participants (planned count) (from the registry)
Sponsor
  • Kardium Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06973031
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06973031. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-10 (actual); primary completion 2028-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Prospective Clinical Study to Evaluate the Safety and Effectiveness of Pulmonary Vein Isolation Plus Box Isolation of Fibrotic Areas With the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation
Acronym
GLOBAL-PF
Condition
Paroxysmal Atrial Fibrillation (PAF)
Condition
Persistent Atrial Fibrillation
Intervention (Device)
Globe Pulsed Field System
Lead sponsor
Kardium Inc. (class: industry)

Record details

Record id
cardio:ct-nct06973031
Content hash
d502ab3188edf95032000f55d353340786918ebef3710362c6fb69ef8f6a8210